SCHEMBL7535667

SCHEMBL7535667

COC(=O)CCc1ccc(C(C)(C)C)cc1O[SiH](C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
EGFR P00533 1/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
NR1H4 Q96RI1 3/20 0.36
ADAM17 P78536 1/20 0.36
LMNA P02545 3/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
CYP2C19 P33261 1/20 0.35
TNF P01375 1/20 0.34
PDE4D Q08499 1/20 0.34
ALOX15 P16050 1/20 0.34
APEX1 P27695 1/20 0.34
MAPK1 P28482 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL305273 0.87 CYP4F2 (0.44) NPSR1NR1H4LMNAALDH1A1MAPT
SCHEMBL7999289 0.86 NPSR1 (0.40) NPSR1EGFRMEN1HTTKMT2A
SCHEMBL4266306 0.86 NPSR1 (0.51) NPSR1NR1H4SMN1; SMN2CYP2C19
SCHEMBL18999228 0.86 NR1H4 (0.47) NPSR1EGFRMEN1HTTKMT2A
SCHEMBL4261597 0.85 TP53 (0.41) NPSR1EGFRMEN1HTTKMT2A
SCHEMBL27565677 0.79 CNR1 (0.47) ADAM17LMNAALDH1A1CNR1CNR2
SCHEMBL18999229 0.78 ALDH1A1 (0.41) NPSR1MEN1HTTKMT2AADAM17
SCHEMBL7586102 0.78 CYP2C19 (0.34) NPSR1EGFRMEN1KMT2AALDH1A1
SCHEMBL8113705 0.77 KLF10 (0.39) EGFRMEN1KMT2AALDH1A1MAPT
SCHEMBL7588465 0.77 MEN1 (0.40) EGFRMEN1HTTKMT2ANR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6414179-B1 USEFUL AGENTS IN THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA, ARTHRITIS, INFLAMMATORY BOWEL DISEASE AND NEURODEGENERATIVE DISEASES BRISTOL-MYERS SQUIBB COMPANY 2002-07-02 US disclosed
US-20020065246-A1 Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2002-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065246-A1 Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors PLA2G4B, PLA2G1B, PLA2R1 NPSR1 2520/4885EGFR 3498/4885MEN1 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.